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Abstract
Background: Exosomes or secreted bi-lipid vesicles from human ESC-derived mesenchymal stem cells (hESC-MSCs)
have been shown to reduce myocardial ischemia/reperfusion injury in animal models. However, as hESC-MSCs are
not infinitely expansible, large scale production of these exosomes would require replenishment of hESC-MSC
through derivation from hESCs and incur recurring costs for testing and validation of each new batch. Our aim was
therefore to investigate if MYC immortalization of hESC-MSC would circumvent this constraint without
compromising the production of therapeutically efficacious exosomes.
Methods: The hESC-MSCs were transfected by lentivirus carrying a MYC gene. The transformed cells were analyzed
for MYC transgene integration, transcript and protein levels, and surface markers, rate of cell cycling, telomerase
activity, karyotype, genome-wide gene expression and differentiation potential. The exosomes were isolated by
HPLC fractionation and tested in a mouse model of myocardial ischemia/reperfusion injury, and infarct sizes were
further assessed by using Evans’ blue dye injection and TTC staining.
Results: MYC-transformed MSCs largely resembled the parental hESC-MSCs with major differences being reduced
plastic adherence, faster growth, failure to senesce, increased MYC protein expression, and loss of in vitro
adipogenic potential that technically rendered the transformed cells as non-MSCs. Unexpectedly, exosomes from
MYC-transformed MSCs were able to reduce relative infarct size in a mouse model of myocardial ischemia/
reperfusion injury indicating that the capacity for producing therapeutic exosomes was preserved.
Conclusion: Our results demonstrated that MYC transformation is a practical strategy in ensuring an infinite supply
of cells for the production of exosomes in the milligram range as either therapeutic agents or delivery vehicles. In
addition, the increased proliferative rate by MYC transformation reduces the time for cell production and thereby
reduces production costs.
Background
Mesenchymal stem cells (MSCs) are multipotent stem
cells that have a limited but robust potential to differ-
entiate into mesenchymal cell types, e.g. adipocytes,
chondrocytes and osteocytes, with negligible risk of tera-
toma formation. MSC transplantation has been used in
clinical trials and animal models to treat musculoskeletal
injuries, improve cardiac function in cardiovascular
disease and ameliorate the severity of graft-versus-host-
disease [1]. In recent years, MSC transplantations have
demonstrated therapeutic efficacy in treating different
diseases but the underlying mechanism has been contro-
versial [2-9]. Some reports have suggested that factors
secreted by MSCs were responsible for the therapeutic
effect on arteriogenesis, stem cell crypt in the intestine,
ischemic injury, and hematopoiesis [9-20]. In support of
this paracrine hypothesis, many studies have observed
that MSCs secrete cytokines, chemokines and growth
factors that could potentially repair injured cardiac tis-
sue mainly through cardiac and vascular tissue growth
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could potentially provide for a non-cell based alternative
for using MSC in treatment of cardiovascular disease
[23]. Non-cell based therapies as opposed to cell-based
therapies are generally easier to manufacture and are
safer as they are non-viable and do not elicit immune
rejection.
We have previously demonstrated that culture med-
ium conditioned by MSCs that were derived from
human embryonic stem cells (HuES9E1 MSCs) or fetal
tissues could protect the heart from myocardial ische-
mia/reperfusion injury and reduce infarct size in both
pig and mouse models of myocardial ischemia/reperfu-
sion (MI/R) injury [24-27]. Subsequent studies demon-
strated that this cardioprotection was mediated by
exosomes or microparticles of about 50-100 hmi nd i a -
meter and these microparticles carry both protein and
RNA load [24-28]. These exosomes could be purified as
a population of homogenously sized particles by size
exclusion on HPLC and reduced infarct size in a mouse
model of MI/R injury at about a tenth of the dosage of
the conditioned medium [24,25].
The identification of exosomes as the therapeutic
agent in the MSC secretion could potentially provides
for a biologic-rather than cell-based treatment modality.
Unlike cells, exosomes do not elicit acute immune rejec-
tion and being non-viable and much smaller, they pose
less safety risks such as the formation of tumor or
embolism. Furthermore unlike cell-based therapies
where there is a need to maintain viability, manufacture
and storage of non-viable exosomes is less complex and
therefore less costly. Besides being therapeutic agents,
exosomes have been advocated as “natural” drug deliv-
ery vehicles [29]. These lipid vesicles could be loaded
with therapeutic agents and be used to deliver the
agents in a cell type specific manner. hESC-MSCs could
be the ideal cellular source for the efficient production
of exosomes. We have demonstrated that these cells
could be grown in a chemically defined medium during
the production and harvest of exosomes and these exo-
somes could be purified by HPLC to generate a popula-
tion of homogenously sized particles [27]. Another
advantage is that these cells were derived from hESC, an
infinitely expansible cell source.
While hESC-MSCs are also highly expansible in cul-
ture, they unlike their parental hESC can undergo only
a finite number of cell divisions before their growth is
arrested and they senesce. Therefore there will be a
need to constantly derive new batches of MSCs from
hESCs to replenish the cell source of exosomes with
each derivation necessitating recurring cost of deriva-
tion, testing and validation. To circumvent this need for
re-derivation and ensure an infinite supply of identical
MSCs for commercially sustainable production of
exosomes as therapeutic agents or delivery vehicle, we
explore the use of oncogenic transformation to bypass
senescence. Oncogenic transformation could potentially
alter the cell biology and affect the production or the
properties of the exosomes. It was previously reported
that transfection of v-MYC gene into fetal MSCs
immortalized the cells but did not alter the fundament
characteristics of these MSCs [30]. Here we transfected
the MSCs with a lentiviral vector containing the MYC
gene which encodes for the MYC protein into the pre-
viously described hESC derived MSCs (HuES9.E1 MSC)
at passage 21 (p21) and passage 16 (p16) to generate a
pooled cell line and three independently derived clonal
cell lines respectively [26]. We examined the trans-
formed cells according to the ISCT minimal defining
criteria for MSCs namely plastic adherence, surface anti-
gen profile of CD29
+,C D 4 4
+,C D 4 9 a
+ CD49e
+,C D 9 0
+,
CD105
+,C D 1 6 6
+,M H CI
+,C D 3 4
-,C D 4 5
- and HLA-
DR
-, and potential to differentiate into adipocytes, chon-
drocytes and osteocytes [31]. The secretion of these
cells was evaluated for the presence of exosomes and
the therapeutic efficacy of these exosomes were tested
in a mouse model of MI/R as previously described [27].
Methods
Oncogenic transformation of HuES9.E1 MSC
The previously described human ESC-derived HuES9.E1
MSCs was infected at p21 or p16 with lentivirus carry-
ing either a MYC gene or a GFP gene to generate two
types of transfected cells, MYC-MSC and GFP-MSC,
respectively. The MYC cDNA was amplified from
pMXs-hc-MYC using primers PTDMYC (5’ GAA TTC
G A AT G CC C CT C AA C GT T AG C3 ’)a n d
PTDMYCa (5’ CTC GAG CGC ACA AGA GTT CCG
TAG C 3’) and cloned into pLVX-puro vector (Clon-
tech, http://www.clontech.com) [32]. Lentiviral particles
were produced using Lenti-X HT Packaging System and
viral titer was determined by using a Lenti-X™ qRT-
PCR titration kit (Clontech, http://www.clontech.com).
The HuES9.E1 MSCs that were infected at p21 were
plated at 10
6 cells per 10 cm dish and infected with
viruses at a MOI = 5 in the presence of 4 μg/ml poly-
brene for overnight [26]. Cells were selected under 2
μg/ml puromycin for three days and expanded as per
human ESC-derived HuES9.E1 MSCs and these cells
were pooled to generate the E1-MYC 21.1 line. For the
HuES9.E1 MSCs that was infected at p16, three inde-
pendently clonal lines (E1-MYC 16.1, E1-MYC 16.2 and
E1-MYC 16.3) were derived by limiting dilution [26].
When the cloned cells were expanded to 10
7 cells (or a
confluent 15 cm culture dish), the passage number was
designated as passage 1.
The cells were analyzed for MYC transgene integra-
tion, transcript and protein levels, surface markers, rate
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wide gene expression and differentiation potential (see
additional file 1).
HPLC purification of exosomes
The instrument setup consisted of a liquid chromato-
graphy system with a binary pump, an auto injector, a
thermostated column oven and a UV-visible detector
operated by the Class VP software from Shimadzu Cor-
poration (Kyoto, Japan). The Chromatography columns
used were TSK Guard column SWXL, 6 × 40 mm and
TSK gel G4000 SWXL, 7.8 × 300 mm from Tosoh Cor-
poration (Tokyo, Japan). The following detectors, Dawn
8 (light scattering), Optilab (refractive index) and QELS
(dynamic light scattering) were connected in series fol-
lowing the UV-visible detector. The last three detectors
were from Wyatt Technology Corporation (California,
USA) and were operated by the ASTRA software. The
components of the sample were separated by size exclu-
sion i.e. the larger molecules will elute before the smal-
ler molecules. The eluent buffer used was 20 mM
phosphate buffer with 150 mM of NaCl at pH 7.2. This
buffer was filtered through a pore size of 0.1 μma n d
degassed for 15 minutes before use. The chromatogra-
phy system was equilibrated at a flow rate of 0.5 ml/
min until the signal in Dawn 8 stabilized at around 0.3
detector voltage units. The UV-visible detector was set
at 220 hm and the column was oven equilibrated to
25°C. The elution mode was isocratic and the run time
was 40 minutes. The volume of sample injected ranged
from 50 to 100 μl .T h eh y d r o d y n a m i cr a d i u s ,R hw a s
computed by the QELS and Dawn 8 detectors. The
highest count rate (Hz) at the peak apex was taken as
the Rh. Peaks of the separated components visualized at
220 hm were collected as fractions for further charac-
terization studies.
Testing secretion for cardioprotection
The conditioned medium was prepared by growing the
transformed MSCs in a chemically defined serum free
culture medium for three days as previously described
[33]. The concentrated conditioned medium was pro-
cessed by HPLC fractionation to obtain the exosomes as
mentioned above. The exosomes were tested in a mouse
model of MI/R injury. Myocardial ischemia was induced
by 30 minutes left coronary artery (LCA) occlusion and
subsequent reperfusion. Five minutes before reperfusion,
mice were intravenously infused with 200 μl saline solu-
tion of 0.3 μg exosome protein purified from culture
medium conditioned by MYC-MSCs. Control animals
were infused with 200 μl saline. After 24 hours reperfu-
sion, infarct size (IS) as a percentage of the area at risk
(AAR) was assessed using Evans’ blue dye injection and
TTC staining as described previously [27]. All animal
experiments were performed in accordance with the
national guidelines on animal care and with prior
approval by the Animal Experimentation Committee of
Utrecht University.
Statistical analysis
Two-way ANOVA with post-hoc Dunnett was used to
test the difference in infarct size between groups. Corre-
lation coefficient of each pairs of array was assessed
using Pearson correlation test.
Results
Transforming HuES9.E1 MSC cultures
HuES9.E1 MSCs at p 21 were infected with either GFP-
or MYC-containing lentivirus. The infected cultures
were placed under the puromycin selection for three
days. Surviving cells were pooled. PCR amplification of
genomic DNA demonstrated that the MYC transgene
was successfully integrated in the genome (Figure 1a).
Unlike the MYC-transfected cells which was pooled to
form the E1-MYC 21.1 line, the GFP-transfected cells
progressed into senescence with decreasing rate of pro-
liferation and acquiring a much flattened, spreading
morphology (Figure 1b) and could not be propagated
more than five passages post-transfection. The MYC-
transformed cells expressed a 100 fold increase in MYC
transcript level relative to the GFP-transfected cells
(GFP-MSCs) (Figure 1c) and higher telomerase activity
(Figure 1d). To generate independently cloned lines,
three HuES9.E1 MSC cultures at p16 were indepen-
dently transfected and placed under puromycin drug
selection. The surviving cell cultures were cloned by
limiting dilution to generate three lines, E1-MYC 16.1,
E1-MYC 16.2 and E1-MYC 16.3 lines, respectively. The
lines were karyotyped by G-banding. The cell morphol-
ogy of all three cell lines was similar to that of E1-MYC
21.1 line. Only E1-MYC 16.3 line had the parental kar-
yotype of 46 XX with a pericentric inversion of chromo-
somal 9 between p11 and q13 in 20/20 metaphases, and
was therefore used in all the subsequent experiments
(Figure 1e) [26]. In contrast to their parental cells, the
MYC-transformed cells proliferated faster with a popula-
tion doubling time of 13 hours versus a population dou-
bling time of 19 hours in untransformed MSCs. The
average cell cycle time as measured using CFDA cell
labelling as previously described was decreased from 19
hours to 11 hours (Figure 1f) [34]. The transformed
cells effectively bypassed senescence and continued to
maintain their proliferative rates for at least another 20
passages. The transformed cells were smaller and
rounder in shape with prominent nuclei. At high cell
density, these cells lose contact inhibition resulting in
the formation of cell clusters (Figure 1b). Consistent
with increased proliferation, the cells had higher levels
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transfected cells (Figure 1d).
Assessment of MYC-MSCs
The MYC-MSC culture were assessed according to the
ISCT minimal criteria for the definition of human
MSCs [31]. As observed earlier (Figure 1b), the culture
did not adhere to plastic culture dishes as well as their
untransformed MSCs especially at confluency when the
cells started to form clusters instead of adhering to the
plastic dish as a monolayer. The surface antigen profile
of the MYC-transformed cells was quite similar to that
of their parental cells except in their negative expression
of MHC I. The cells were CD29
+,C D 4 4
+, CD49a
+
CD49e
+,C D 7 3
+,C D 9 0
+,C D 1 0 5
+,C D 1 6 6
+,M H CI
-,
HLA-DR
-, CD34
- and CD45
- (Figure 2). The in vitro dif-
ferentiation potential of both polyclonal E1-MYC 21.1
and monoclonal E1-MYC 16.3 cell lines was next exam-
ined (Figure 3). Both cell lines differentiated readily into
chondrocytes and osteocytes (Figure 3a, b) but not adi-
pocytes. The induction of adipogenesis in MSCs
required 4 cycles of a 6-day treatment protocol consist-
ing of 3 days’ exposure to induction medium and 3
days’ exposure to maintenance medium. We observed
that exposure to the induction medium induced death
in the MYC-transformed cells but not the untrans-
formed parental cells (Figure 3c). These observations
suggested that MYC-transformed cells cannot undergo
adipogenic differentiation. Together, these observations
demonstrated that unlike a previous report where MYC
transformation was observed not to alter the fundamen-
tal characteristics of MSCs, we observed here that MYC
transformation affected a defining property of MSCs i.e.
the potential to undergo adipogenesis [30].
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Figure 1 Transformation of hESC-MSC. (a) PCR analysis of cellular DNA from MYC-transfected HuES9.E1 MSCs (E1-MYC 21.1), GFP transfected
HuES9.E1 MSCs (E1-GFP) and the parental MSCs, HuES9.E1 (E1). DNA was amplified using primers specific for MYC exon 2 and exon 3,
respectively. The expected PCR fragment size for the endogenous MYC gene was1.7 kb and for the transfected MYC cDNA was 0.36 kb as
represented by the amplified fragment from the MYC-lentivirus. (b) Cell Morphology of transfected MSCs as observed under light microscopy. (c)
Quantitative RT-PCR was performed on RNA from different passages of E1-MYC 21.1 and GFP-MSCs for the level of MYC and ACTIN mRNA. The
relative MYC-transcript level was normalized to that in GFP-MSCs. (d) Relative telomerase activity. 1 μg of cell lysate protein was first used to
extend a TS primer by telomerase activity and the telomerase product was then quantitated by real time PCR. The Ct value represented the
amount of telomerase product and was therefore indirectly proportional to telomerase activity in the lysate. (e) Karyotpye analysis of E1-MYC
16.3 by G-banding. (f) Rate of cell cycling. Cells were labelled with CFDA and their fluorescence was monitored over time by flow cytometry. The
loss of cellular fluorescence at each time point was used to calculate the number of cell division that the cells have undergone as described in
Materials and Methods (Additional files 1).
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G e n o m e - w i d eg e n ee x p r e s s i o np r o f i l i n go fMYC-trans-
formed MSCs and their parental MSCs by microarray
hybridisation was performed to assess the relatedness
between the cell types. Microarray hybridization was
performed in duplicate on Sentrix Human Ref-8 Expres-
sion BeadChip using RNA from E1-MYC 16.3 MSCs at
p4, p7, and p8, and from the parental HuES9-E1 MSCs
at p15 and p16. The gene expression profile (Accession
number: GSE25296) among different passages of E1-
MYC 16.3 MSCs or among different passages of the par-
ental HuES9-E1 MSCs was highly similar with a correla-
tion coefficient, r
2 being greater than 0.98. The
correlation coefficient, r
2 between E1-MYC 16.1 MSCs
and parental HuES9-E1 MSCs, was also relatively high
at 0.92 (Figure 4a). A total of 161 genes was upregulated
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Figure 2 Surface antigen profiling. HuES9.E1 and E1-MYC 16.3 MSCs were stained with an appropriate antibody conjugated to a fluorescent
dye and analyzed by FACS. The fluorescence of HuES9.E1 or E1-MYC 16.3 was the average cellular fluorescence of cells at p16 or p6. Nonspecific
fluorescence was assessed by incubating the cells with isotype-matched mouse monoclonal antibodies.
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16.1 MSCs suggesting that there were changes in gene
expression after MYC transformation. These differen-
tially expressed genes were functionally clustered by
PANTHER (Protein ANalysis THrough Evolutionary
Relationships) in which the observed frequency of genes
for each biological process in each gene set was com-
pared with the reference frequency which, in this case is
the frequency of genes for that biological process in the
NCBI database [35,36]. There were 11 over-represented
biological processes for the 161 upregulated genes
namely, metabolic process, nucleobase, nucleoside,
nucleotide and nucleic acid metabolic process, primary
metabolic process, amino acid transport, sulfur meta-
bolic process, organelle organization, mitochondrion
organization, peroxisomal transport, cellular amino acid
and derivative metabolic process, polyphosphate cata-
bolic process and protein metabolic process. There were
4 under-represented processes: vesicle-mediated trans-
port, exocytosis, cell surface receptor linked signal
transduction, and immune system process (Figure 4b).
In the 226 downregulated genes, there were 37 over-
and 1 under-represented biological processes (Figure
4c).
For the up-regulated genes, many of the associated
over-represented processes were generally important for
increasing cell mass or anabolic activity for cell division
and were consistent with the observed increased cell
proliferation activity. The under-represented processes,
namely vesicle-mediated transport, exocytosis suggested
that exosome production might not be affected. For the
down-regulated genes, the 37 over-represented processes
could be broadly classified into processes that are asso-
ciated with adhesion, differentiation, communication,
immune response, cell death and metabolism. These
processes were also consistent with some of our obser-
vations of the MYC-transformed MSCs, namely reduced
adherence to plastic, loss of adipogenic differentiation
potential and loss of MHC I expression.
Cardioprotective activity of secretion
The loss of adipogenic potential in MYC-transformed
MSC suggested that other aspects of the characteristics
of ESC-derived MSCs such as the production of thera-
peutic exosomes might also be compromised by the
transformation. We had previously demonstrated that
exosomes secreted by ESC-derived MSCs was protective
in a mouse model of MI/R injury [27]. To test if this
aspect was compromised, the transformed cells were
grown in a chemically defined medium, the conditioned
culture medium harvested and exosomes were purified
as previously described [24,33]. Despite increased MYC
transcript and protein levels in the transformed cells,
MYC protein was not detectable in the conditioned
medium and purified exosomes (Figure 5a). The HPLC
protein profile of the conditioned medium was similar
to that of conditioned medium from untransformed
MSCs (Figure 5b) with the fastest eluting fraction having
a retention time of about 12 minutes [24]. Dynamic
light scattering analysis of this peak revealed the pre-
sence of particles that were within a hydrodynamic
radius range of 50-65 hm. In a typical run, we routinely
purified about 1.5 mg of exosomes per liter of condi-
tioned medium. HPLC-purified exosomes from either
E1-MYC 21.1 or E1-MYC 16.3 was administered to the
m o u s em o d e lo fM I / Ri n j u r ya tad o s a g eo f0 . 3o r0 . 4
μg per mouse respectively (Figure 5c). The area at risk
(AAR) as a percentage of left ventricular (LV) area in
E1-MYC 21.1 exosome, E1-MYC 16.3 exosome, or the
saline-treated control group was similar at 39.1 ± 3.4%
(n = 5), 41.7 ± 4.7% (n = 4) and 40.8 ± 11.8% (n = 10),
respectively. The relative infarct size (IS/AAR) in mice
treated with E1-MYC 21.1 exosome or E1-MYC 16.3
exosome was 23.4 ± 8.2%, and 22.6 ± 4.5%, respectively
E1-MYC 16.3 
day 2 day 2
E1-MYC 16.3  HuES9.E1
E1-MYC 16.3 
a)
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Osteogenesis
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Figure 3 Differentiation of HuES9E1 and E1-MYC 16.3 MSCs.
MSCs were induced to undergo a) osteogenesis and then stained
with von Kossa stain; b) chondrogenesis and then stained with
Alcian blue; c) adipogenesis where E1-MYC 16.3 and HuES9E1 MSCs
were exposed to adipogenesis induction medium for two days. The
cells were viewed at 100 × magnification.
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Figure 4 Gene expression analysis. RNA from HuES9E1 and E1-MYC 16.3 MSCs were hybridized to Sentrix HumanRef-8 Expression BeadChip
Version 3 and analyzed by Beadstudio and Genespring GX 10. a) Pairwise comparison of gene expression between HuES9.E1 and E1-MYC 16.3
MSCs using Beadstudio analysis. b,c) PANTHER analysis. 161 genes that were over-expressed by > 2-fold and 226 under-expressed genes that
were under-expressed by > 2-fold in E1-MYC 16.3 MSCs were analyzed using PANTHER algorithm. The observed frequency of genes for each
biological process in each gene set was compared with the reference frequency which, in this case is the frequency of genes for that biological
process in the NCBI database. Those biological processes whose observed frequency exceeds the reference frequency with a p < 0.05 are
considered significant.
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Page 7 of 10and their relative infarct sizes were significantly lower
than the relative infarct size of 38.5 ± 5.6% in saline-
treated mice (p < 0.001 and p < 0.002, respectively).
Discussion
This report describes the transformation of human ESC-
derived MSCs by over-expression of MYC gene. This
transformation enabled the cells to bypass senescence,
increase telomerase activity and enhance proliferation.
Generally, genome-wide gene expression between the
transformed cells versus their parental cells was con-
served with a correlation coefficient of 0.92. The trans-
formed cells also have the characteristic surface antigen
profile: CD29
+,C D 4 4
+,C D 4 9 a
+, CD49e
+,C D 9 0
+,
CD105
+, CD166
+,M H CI
-,H L A - D R
-, CD34
- and CD45
-
. Although the transformed cells fulfilled most of funda-
mental requisites in ISCT minimal criteria for the defi-
nition of human MSCs, they nevertheless have an
altered MSC phenotype [31]. They exhibited reduced
adherence to plastic and failed to undergo adipogenesis
which ironically was reported to be most robust among
the three fundamental MSC differentiation potentials in
the human ESC-derived MSCs [26]. Therefore, in con-
trast to a previous report that observed no fundamental
changes in MSC properties after MYC transformation,
we observed some fundamental changes in MYC-
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Figure 5 Analysis of secretion. (a) Western blot analysis. Proteins from cell lysate, conditioned medium (CM), and HPLC purified exosomes of
E1MSCs or E1-MYC-MSCs were separated on SDS-PAGE and probed with different antibodies to detect MYC (64 kDa), ACTIN (42 kDa), and CD9
(24 kDa). (b) HPLC fractionation and dynamic light scattering of CM from E1-MYC-MSC. CM was fractionated on a HPLC using BioSep S4000, 7.8
mm × 30 cm column. The components in CM were eluted with 20 mM phosphate buffer with 150 mM of NaCl at pH 7.2. The elution mode
was isocratic and the run time was 40 minutes. The eluent was monitored for UV absorbance at 220 hm. Each eluting peak was then analyzed
by light scattering. The fastest eluting peak (arrow) was collected for testing in a mouse model of myocardial ischemia/reperfusion injury. (c) 0.3
μg HPLC-purified exosomes was administered intravenously to a mouse model of acute myocardial/ischemia reperfusion injury five minutes
before reperfusion. Infarct size (IS) as a percentage of the area at risk (AAR) upon treatment with saline (n = 10), exosomes from E1-MYC 21.1 (n
= 5) and exosomes from E1-MYC 16.3 (n = 4) were measured. The relative infarct size (IS/AAR) in mice treated with E1-MYC 21.1 exosome or E1-
MYC 16.3 exosome was 23.4 ± 8.2%, and 22.6 ± 4.5%, respectively and their relative infarct sizes were significantly lower than the relative infarct
size of 38.5 ± 5.6% in saline-treated mice (p < 0.001 and p < 0.002, respectively).
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Page 8 of 10transformed cells such that the cells no longer fulfilled
the ISCT minimal criteria for the definition of human
MSCs and are technically not MSCs [30,31]. Despite
the loss of a defining MSC property, the MYC-trans-
formed cells continued to secrete exosomes that could
reduce infarct size in a mouse model of MI/R injury.
The relative infarct size was 23.4 ± 8.2% and 22.6 ±
4.5% in mice treated with exosomes from the polyclo-
nal and monoclonal lines, respectively. The relative
infarct size in saline treated mice was 38.5 ± 5.6%.
These relative infarct sizes were comparable to those
observed in mice treated with exosomes from the
untransformed parental MSCs or fetal MSCs [24,25].
The relative infarct sizes in mice treated with these
exosomes were 17.0 ± 3.6% and 18.1 ± 2.0%, respec-
tively against a 34.5 ± 3.3% in saline treated mice.
Therefore, both independently transformed polyclonal
and monoclonal lines also produced exosomes with
similar therapeutic efficacy as those produced by
untransformed MSCs indicating that exosome produc-
tion was independent of the transformation and was
consistent and reproducible. The significant reduction
of infarct size by exosome treatment and the well
established correlation between infarct size and subse-
quent adverse remodeling suggests that exosome treat-
ment would enhance the prognostic outcome of
reperfusion therapy [37]. We noted that MYC protein
was present in the transformed cells but was not
detectable in either the conditioned medium or exo-
some. As onco-protein unlike oncogene cannot be
replicated or amplified, the risk of tumorigenesis by
exosomes from MYC-transformed cells is further miti-
gated. The use of lentiviral vectors for the transforma-
tion of the cells poses another potential safety risk.
Since the secreted exosome and not the transformed
cells will be used as therapeutic agents, the risk from
the integration of lentivirus is mitigated. Also the use
of newer generation of lentiviral vector which in our
case is a third generation lentiviral vector further
reduces the risk of producing infectious recombinant
viral particles. For the actual manufacture of therapeu-
tic exosomes, we propose transforming the cells using
some of the lentiviral vectors that are currently being
tested in clinical trials [38]. This will further reduce
the risks associated with the use of lentiviral vectors
for transformation.
Conclusion
In summary, MYC transformation represents a practical
strategy in ensuring an infinite supply of cells for the
production of exosomes in the milligram range as either
therapeutic agents or delivery vehicles. In addition, the
increased proliferative rate reduces the time for cell pro-
duction and thereby reduces production costs. In
conclusion, this work despite the lack of exciting novel
scientific insights into biological processes provides a
critical enabling technology for the development of a
cost effective production process for consistent supplies
of HPLC-purified therapeutic human exosomes.
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